RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makina Sanayi Ticaret A.S.
BBIST:RTALB2.18
TRY
+0.19
(+9.55%)
ISIN
TRERTAL00018
Return %
Stock
S&P 500
1Y
-42.48
14.20
3Y
-20.84
81.12
5Y
20.33
68.34
Capital Structure
TRY
•
in mil. unless spec.Working Capital
TRY
•
in mil. unless spec.Growth Rates
TRY
•
in mil. unless spec.Quarterly Revenue
TRY
•
in mil. unless spec.Quarterly Earnings Per Share
TRY
•
in mil. unless spec.Quarterly Dividends Per Share
TRY
•
in mil. unless spec.Company Description
- CEO
- Saban Orçun Kalkan
- Full Time Employees
- 81
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Gebze Turkey
- IPO Date
- Jun 2, 2014
- Website
- rtalabs.com.tr
- Similar Companies
- Business
- RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makina Sanayi Ticaret A.S. is a Turkey-based biotechnology and medical diagnostics company that specializes in the research, development, manufacturing, and distribution of in vitro diagnostic (IVD) medical devices, molecular biology products, microbiological culture media, and laboratory automation systems. Founded in 1996 and headquartered in Gebze, Kocaeli, the company operates within the Guler Yatirim Holding corporate ecosystem. RTA Laboratuvarlari serves a diverse client base comprising public and private hospital networks, clinical diagnostic laboratories, academic research institutions, blood banks, pharmaceutical manufacturers, and food quality control laboratories across Turkey, while exporting its products to international markets across Europe, the Middle East, Central Asia, and Africa. The company operates across multiple specialized business segments, offering an extensive portfolio of medical and industrial diagnostic products. Its primary offerings comprise molecular biology and diagnostic solutions, including real-time quantitative polymerase chain reaction (qPCR) kits, multiplex infectious disease panels, magnetic bead-based and spin column nucleic acid extraction kits, automated RNA/DNA isolation instruments, viral transport media, and master mixes; clinical microbiology products, including ready-to-use prepared culture media in Petri dishes, tubes, and bottles, chromogenic culture media, dehydrated culture media, antibiotic susceptibility discs, transport swabs, and automated blood culture systems; industrial microbiology supplies, including environmental monitoring contact plates, gamma-irradiated isolator media, sterility testing media, and hygiene control solutions for pharmaceutical, cosmetics, and food manufacturing environments; serology and rapid diagnostic testing products, including lateral flow immunochromatographic rapid test cassettes, ELISA test kits, blood grouping reagents, diagnostic staining solutions, and clinical chemistry reagents; and laboratory equipment and consumables, including automated liquid handling workstations, thermal cyclers, spectrophotometers, benchtop laboratory centrifuges, and disposable plastic consumables. Additionally, the company provides contract development and manufacturing (CDMO/OEM) services, laboratory setup consultation, technical maintenance, and protocol validation services. In recent operations, RTA Laboratuvarlari has executed key strategic expansions, facility upgrades, and targeted biopharmaceutical investments. The company expanded and modernized its production and R&D infrastructure at its Gebze Plastikciler Organized Industrial Zone facility to enhance manufacturing automation and increase capacity for molecular diagnostic kits and high-throughput extraction platforms. Strategically, RTA Laboratuvarlari has diversified its healthcare footprint through participation in strategic biopharmaceutical ventures, including investment in Maxicells Ilac Sanayi A.S. to support domestic plasma fractionation and blood-derived product development, alongside venture investments executed in partnership with A1 Girisim Sermayesi Yatirim Ortakligi A.S. Furthermore, the company has broadened its commercial product line with next-generation multiplex respiratory and gastrointestinal PCR panels, pursued ongoing alignment with European In Vitro Diagnostic Medical Devices Regulation (IVDR) compliance standards, and entered into new international distribution partnerships to expand its global market penetration.